Strategic Advisory Partners’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.99M Sell
9,448
-919
-9% -$184K 1.37% 7
2026
Q2
$1.97M Sell
10,367
-3,428
-25% -$589K 1.4% 8
2026
Q1
$2.33M Sell
13,795
-15,440
-53% -$2.64M 1.83% 7
2025
Q4
$4.93M Buy
+29,235
New +$4.75M 4.09% 6

Other funds holding IBB

Strategic Advisory Partners's IBB Position: Q3 2026 in Review

Strategic Advisory Partners reduced its iShares Biotechnology ETF (IBB) stake by 8.9% in Q3 2026, selling an estimated $184K and leaving 9,448 shares worth $1.99M. The position accounts for 1.37% of the portfolio, ranked #7.

Strategic Advisory Partners first reported a position in IBB in Q4 2025 and has held it in 4 quarters since. The position peaked at $4.93M in Q4 2025. 1,031 funds tracked by Wall St. Rank hold IBB as of Q3 2026.

  • Strategic Advisory Partners held 9,448 shares of iShares Biotechnology ETF worth $1.99M as of Q3 2026.
  • Strategic Advisory Partners sold 919 iShares Biotechnology ETF shares in Q3 2026, an estimated $184K.
  • iShares Biotechnology ETF made up 1.37% of Strategic Advisory Partners's portfolio in Q3 2026, its #7 holding.
  • Strategic Advisory Partners first reported a position in iShares Biotechnology ETF in Q4 2025 and has held it in 4 quarters since.
  • Strategic Advisory Partners's iShares Biotechnology ETF position peaked at $4.93M in Q4 2025.
  • 1,031 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2026.

Based on Strategic Advisory Partners's 13F filing for Q3 2026, filed 6 Nov 2026.